Pfizer (PFE) Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Pfizer (PFE) Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age

Mizuho Securities Reiterates Buy Rating on Pfizer (PFE) After Speaking with Management

May 18, 2020 7:01 AM EDT

Mizuho Securities analyst Vamil Divan reiterated a Buy rating and $42.00 price target on Pfizer (NYSE: PFE) following a conference call with management. Pfizer released updated data on their Duchenne Muscular Dystrophy (DMD) candidate at ASGCT.

Divan's overall conclusion is unchanged in that the... More

Pfizer (PFE) Reports New Phase 1b Results of Gene Therapy in Ambulatory Boys with DMD Support Advancement into Pivotal Phase 3 Study

May 15, 2020 8:02 AM EDT

Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary data from 9 ambulatory boys with DMD, aged 6 to 12 (mean age: 8 years) indicate that the intravenous administration of PF-06939926 was well-tolerated during the infusion period, with encouraging efficacy and manageable safety events, even when considering those adverse events that were more severe in nature. The treatment provided durable and statistically significant improvements across multiple efficacy-related endpoints measured at 12 months post-infusion, including sustained levels of mini-dystrophin expression and improvements... More